NOVI, GIOVANNI
 Distribuzione geografica
Continente #
EU - Europa 3.033
AS - Asia 194
SA - Sud America 21
NA - Nord America 20
AF - Africa 3
Totale 3.271
Nazione #
IT - Italia 3.024
SG - Singapore 88
VN - Vietnam 49
CN - Cina 44
US - Stati Uniti d'America 15
BR - Brasile 12
AR - Argentina 7
HK - Hong Kong 4
FR - Francia 3
MX - Messico 3
BD - Bangladesh 2
JP - Giappone 2
MA - Marocco 2
RU - Federazione Russa 2
BE - Belgio 1
BH - Bahrain 1
BY - Bielorussia 1
CA - Canada 1
CH - Svizzera 1
CO - Colombia 1
HT - Haiti 1
JO - Giordania 1
PK - Pakistan 1
PY - Paraguay 1
RO - Romania 1
SA - Arabia Saudita 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 3.271
Città #
Genoa 1.200
Genova 1.177
Rapallo 329
Vado Ligure 304
Singapore 25
Beijing 19
Ho Chi Minh City 19
Ashburn 12
Hanoi 12
Savona 5
Bordighera 4
Hong Kong 4
Haiphong 3
Mexico City 3
Tianjin 3
Can Tho 2
Lấp Vò 2
Phủ Lý 2
Tokyo 2
Altamira 1
Amman 1
Asunción 1
Bauru 1
Belo Horizonte 1
Biên Hòa 1
Bologna 1
Brest 1
Bucharest 1
Bắc Giang 1
Bắc Ninh 1
Cotia 1
Curitiba 1
Dhaka 1
El Galpón 1
Feni 1
Frutal 1
Grand Bourg 1
Hamad Town 1
Jeddah 1
Jhelum 1
Johannesburg 1
Lanús 1
Liège 1
Los Angeles 1
Marília 1
Medellín 1
Montreal 1
Natal 1
New York 1
Ninh Bình 1
Pavia 1
Port-au-Prince 1
Porto Alegre 1
Posadas 1
Quilmes 1
Quảng Ngãi 1
Rosario 1
San Justo 1
Santa Maria da Vitória 1
Tashkent 1
Thái Bình 1
Tramandaí 1
Tétouan 1
Vĩnh Long 1
Xaxim 1
Zurich 1
Totale 3.174
Nome #
Clinical epidemiology of amyotrophic lateral sclerosis in Liguria, Italy: An update of LIGALS register 180
Different MRI patterns in MS worsening after stopping fingolimod 178
Relationship between retinal inner nuclear layer, age, and disease activity in progressive MS 159
Ghost spasticity in multiple sclerosis 158
The therapeutic effect of mesenchymal stem cell transplantation in experimental autoimmune encephalomyelitis is mediated by peripheral and central mechanisms 156
A PET/CT approach to spinal cord metabolism in amyotrophic lateral sclerosis 155
Dramatic rebounds of MS during pregnancy following fingolimod withdrawal. 155
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience 139
Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders 133
Acute disseminated encephalomyelitis after SARS-CoV-2 infection 133
Tocilizumab in MOG-antibody spectrum disorder: a case report 123
Ocrelizumab does not impair B- and T-cell responses to primary VZV infection in a patient with MS 123
Longitudinal brain magnetic resonance imaging and real-time quaking induced conversion analysis in presymptomatic Creutzfeldt-Jakob disease 121
Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population 116
Impact of treatment on cellular immunophenotype in MS: A cross-sectional study 106
Assessing upper limb function in Multiple Sclerosis by an engineered glove 105
Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy 99
Towards clinical application of mesenchymal stem cells for treatment of neurological diseases of the central nervous system. 98
Case Report: Post-COVID-19 Vaccine Recurrence of Guillain-Barré Syndrome Following an Antecedent Parainfectious COVID-19-Related GBS 92
Fulminant Hepatitis Associated with Echovirus 25 during Treatment with Ocrelizumab for Multiple Sclerosis 87
Interleukin-6 Receptor Blockade in Treatment- Refractory MOG-Ab–Associated Disease and Neuromyelitis Optica Spectrum Disorders 86
COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? 85
Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis 77
Alpha-synuclein seeds in olfactory mucosa and cerebrospinal fluid of patients with dementia with Lewy bodies 76
Tailoring B cell depletion therapy in MS according to memory B cell monitoring 72
Relationship Between Retinal Layer Thickness and Disability Worsening in Relapsing-Remitting and Progressive Multiple Sclerosis 71
Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic? 69
Brain lesion microstructure in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein disease 54
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study 46
Relapsing meningitis and limbic encephalitis in anti-AQP4-Ab-associated neuromyelitis optica spectrum disorder 36
Vaccinations in patients with multiple sclerosis: a real-world, single-center experience 36
Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study 29
Totale 3.353
Categoria #
all - tutte 13.644
article - articoli 13.268
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.912


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021133 0 0 0 0 0 15 19 21 18 31 16 13
2021/2022297 11 7 12 24 17 20 12 67 16 38 29 44
2022/2023396 38 38 8 48 42 63 2 23 66 4 57 7
2023/2024315 14 26 3 36 20 68 57 13 16 18 10 34
2024/2025793 59 49 18 57 97 76 98 151 38 21 75 54
2025/2026608 198 29 77 79 209 16 0 0 0 0 0 0
Totale 3.353